Business Description
InspireMD Inc
NAICS : 339112
SIC : 3841
ISIN : US45779A8466
Total Employee Number:
127Description
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 10.06 | |||||
Equity-to-Asset | 0.71 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | -0.06 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -11.49 | |||||
Beneish M-Score | -3.37 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -40.3 | |||||
3-Year EBITDA Growth Rate | 31.3 | |||||
3-Year EPS without NRI Growth Rate | 31.4 | |||||
3-Year FCF Growth Rate | 34.5 | |||||
3-Year Book Growth Rate | -15.3 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 35.59 | |||||
9-Day RSI | 44.27 | |||||
14-Day RSI | 48.66 | |||||
3-1 Month Momentum % | -9.25 | |||||
6-1 Month Momentum % | -54.83 | |||||
12-1 Month Momentum % | -69.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.8 | |||||
Quick Ratio | 3.52 | |||||
Cash Ratio | 3.15 | |||||
Days Inventory | 129.78 | |||||
Days Sales Outstanding | 66.78 | |||||
Days Payable | 66.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -73.5 | |||||
Shareholder Yield % | -100.02 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 18.05 | |||||
Operating Margin % | -494.03 | |||||
Net Margin % | -484.11 | |||||
EBITDA Margin % | -488.7 | |||||
FCF Margin % | -391.67 | |||||
OCF Margin % | -380.13 | |||||
ROE % | -122.23 | |||||
ROA % | -92.94 | |||||
ROIC % | -413.06 | |||||
3-Year ROIIC % | -371.18 | |||||
ROC (Joel Greenblatt) % | -853.87 | |||||
ROCE % | -115.11 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 5.8 | |||||
PB Ratio | 1.16 | |||||
Price-to-Tangible-Book | 1.16 | |||||
EV-to-EBIT | -0.17 | |||||
EV-to-EBITDA | -0.17 | |||||
EV-to-Revenue | 0.84 | |||||
EV-to-Forward-Revenue | 2.3 | |||||
EV-to-FCF | -0.22 | |||||
Price-to-GF-Value | 0.48 | |||||
| Price-to-Net-Current-Asset-Value | 1.56 | |||||
| Price-to-Net-Cash | 2.11 | |||||
Earnings Yield (Greenblatt) % | -588.24 | |||||
FCF Yield % | -116.22 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NSPR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
InspireMD Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 10.841 | ||
| EPS (TTM) ($) | -0.64 | ||
| Beta | 0.0638 | ||
| 3-Year Sharpe Ratio | -0.56 | ||
| 3-Year Sortino Ratio | -0.81 | ||
| Volatility % | 60.35 | ||
| 14-Day RSI | 48.66 | ||
| 14-Day ATR ($) | 0.067112 | ||
| 20-Day SMA ($) | 0.879513 | ||
| 12-1 Month Momentum % | -69.13 | ||
| 52-Week Range ($) | 0.63 - 2.565 | ||
| Shares Outstanding (Mil) | 46.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
InspireMD Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
InspireMD Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 08:30 | In 57 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 56 days | ||
| H.C. Wainwright 28(th) Annual Global Investment Conference | 2026-09-14 14:30 | In 6 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-17 08:30 | 0.98 (+15.59%) | ||
| Second quarter earnings results for 2026 | 2026-08-17 | 0.98 (+15.59%) | ||
| General meeting for 2026 | 2026-06-03 10:00 | 1.01 (+1.00%) | ||
| Guidance call for 2026 | 2026-05-13 16:20 | 1.20 (-3.23%) | ||
| First quarter earnings conference call for 2026 | 2026-05-04 16:30 | 1.15 (-1.71%) | ||
| First quarter earnings results for 2026 | 2026-05-04 | 1.15 (-1.71%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-14 12:45 | 1.35 (+3.05%) |
Show
Entries
InspireMD Inc Frequently Asked Questions
What is InspireMD Inc(NSPR)'s stock price today?
The current price of NSPR is $0.78. The 52 week high of NSPR is $2.57 and 52 week low is $0.63.
When is next earnings date of InspireMD Inc(NSPR)?
The next earnings date of InspireMD Inc(NSPR) is 2026-11-04 Est..
Does InspireMD Inc(NSPR) pay dividends? If so, how much?
InspireMD Inc(NSPR) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers